<DOC>
	<DOCNO>NCT01177007</DOCNO>
	<brief_summary>This study open label prospective trial TheraSphere treatment patient liver metastasis fail intolerant systemic liver direct therapy . Patients treat TheraSphere dose 120 ± 10 % Gy , follow time progression ( TTP ) , safety , overall survival .</brief_summary>
	<brief_title>Intra-arterial Y-90 TheraSpheres Hepatic Metastases From Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 18 year age old , Patients diagnosis metastatic disease liver fail intolerant systemic liver direct therapy . A patient consider fail systemic liverdirected therapy , opinion refer physician , patient progression disease receive standard approve therapy . Specifically , patient fail first line chemotherapy ( standard approve therapy particular solid tumor ) , time period design ass particular regimen ( least 30 day ) , may enrol protocol . A patient intolerant systemic liverdirected therapy , opinion refer physician , example , patient unable tolerate appropriate chemotherapy , patient residual toxicity previous therapy ( e.g . neuropathy oxaliplatin ) , patient 's performance status treatment systemic therapy would result excessive toxicity . Liver metastases unresectable Target tumor measurable use standard image technique Tumor replacement ≤ 70 % total liver volume base visual estimation Investigator Tumors hypervascular base visual estimation Investigator Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 02 At least one month elapse since recent prior cancer therapy follow exception Patients receive Sandostatin treatment Neuroendocrine cancer may enrol continue Sandostatin treatment . Patients receive antioestrogen therapy breast cancer may continue treatment therapy initiate great 30 day prior TheraSphere treatment . Chemotherapy may continue evidence progression , liver , treatment provide change therapy 1 month prior TheraSphere treatment immediate chemotherapeutic toxicity complicate TheraSphere treatment resolve . In case , chemotherapy may continue continue control extrahepatic disease . Patient willing participate study sign study inform consent Exclusion Criteria At risk hepatic renal failure , indicate follow pretreatment laboratory clinical finding within 28 day treatment : Serum creatinine &gt; 2.0 mg/dL , unless dialysis Serum total bilirubin ≥ 2.0 mg/dL Albumin &lt; 2.0 g/dL Any history hepatic encephalopathy Contraindications angiography selective visceral catheterization may include , limited , follow : Any bleed diathesis coagulopathy correctable usual therapy hemostatic agent ( e.g. , closure device ) Severe peripheral vascular disease preclude catheterization History severe allergy intolerance contrast agent , narcotic , sedative atropine manage medically . Severe liver dysfunction presentation pulmonary insufficiency clinically evident history chronic obstructive pulmonary disease Cirrhosis portal hypertension Previous external beam radiation treatment liver Any intervention , compromise Ampulla Vater Clinically evident ascites . ( Note : A radiographic finding trace ascites image acceptable ) . Any continue complication prior cancer therapy improve resolve prior 21 day first treatment TheraSphere ( investigator determine continue complication compromise safety patient follow treatment TheraSphere ) . In judgment physician , significant lifethreatening extrahepatic disease Concurrent enrollment another clinical study Evidence technetium99m macroaggregated albumin ( 99mTcMAA ) scan demonstrate lung shunt potential absorb dose radiation lung &gt; 30 Gy . The 30 Gy limit cumulative limit infusion TheraSphere . Evidence technetium99m macroaggregated albumin ( 99mTcMAA ) scan demonstrate potential deposition microspheres gastrointestinal tract correct placement catheter distal collateral vessel use standard angiographic technique , coil embolization . A positive serum pregnancy test woman childbearing potential In Investigator 's judgment , comorbid disease condition event ( e.g. , recent myocardial infarction ) would place patient undue risk , would preclude safe use TheraSphere</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Neoplastic Processes</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Neuroectodermal Tumors</keyword>
	<keyword>Neoplasms , Germ Cell Embryonal</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Neoplasms , Nerve Tissue</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Carcinoma , Neuroendocrine</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Digestive System Diseases</keyword>
</DOC>